In this review, we will discuss the molecular characteristics of the HDAC6 protein, as well as its overexpression in CML leukemic stem cells, which make it a promising therapeutic target for the treatment of CML. This evidence concerns the gene HDAC6 and chronic myelogenous leukemia, BCR-ABL1 positive.